Literature DB >> 26996489

Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.

Zeng-Zhi Lian, Yi-Feng Sun, Cheng Chen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26996489      PMCID： PMC4819314          DOI： 10.4103/0366-6999.178964

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  3 in total

Review 1.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

2.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245
  3 in total
  3 in total

Review 1.  Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.

Authors:  Ana P S Silva; Priscila V Coelho; Maristella Anazetti; Patricia U Simioni
Journal:  Hum Vaccin Immunother       Date:  2016-11-10       Impact factor: 3.452

2.  Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma.

Authors:  Ling Ding; Yehan Zhu; Cheng Chen
Journal:  Ther Adv Respir Dis       Date:  2016-11-30       Impact factor: 4.031

3.  A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia.

Authors:  Chao Liu; Ling Ding; Ye-Han Zhu; Cheng Chen
Journal:  Ther Clin Risk Manag       Date:  2017-10-12       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.